In this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Observe 4D real-world study.
Read More »John Buse Part 1, The Latest Exciting Diabetes Info
In part 1 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about his excitement over the information presented at the ADA conference about the GLP-1 and SGLT-2 drugs, and how to implement their use.
Read More »John Buse Part 2, Observe 4D Study
In part 2 of this Exclusive Interview, John Buse explains the Observe 4D real-world study, which looked at the relationship between the use of SGLT-2 and heart failure and amputation outcomes, in a conversation with Diabetes in Control Publisher Steve Freed.
Read More »John Buse Part 3, SGLT2 Inhibitors Effects On Amputations And Cardiovascular Disease
In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.
Read More »John Buse Part 4, Are Insurance Companies Willing To Pay For SGLT2 Inhibitors?
In part 4 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about insurance coverage of SGLT-2 drugs and the challenges for patients with heart and kidney issues.
Read More »John Buse Part 5, Other Uses For SGLT2 Inhibitors
In part 5 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about studies on the use of SGLT in other populations — people without diabetes, people with kidney disease, etc.
Read More »John Buse Part 6, Observe 4D Study Versus Other SGLT2 Studies
In part 6 of this Exclusive Interview, John Buse compares the Observe 4D study to other similar studies in a conversation with Diabetes in Control Publisher Steve Freed.
Read More »John Buse Part 7, What Do You Want Practitioners To Take Away From This Study?
In part 7 of this Exclusive Interview, John Buse urges other medical professionals to weigh the risks and benefits of using SGLT in a conversation with Diabetes in Control Publisher Steve Freed.
Read More »John Buse Part 8, SGLT2 Inhibitors For Type 1 Diabetes
In part 8, the conclusion of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the good and bad effects of using SGLT2 for patients who have type 1.
Read More »Lisa Latts 2018 Complete Interview
Lisa M. Latts MD, MSPH, MBA, FACP is Deputy Chief Health Officer for IBM Watson Health. She is a national leader in health care quality and has nearly 20 years’ experience in health care delivery working to improve lives for patients. She has worked as a health insurance executive, a consultant and for one of the nation’s leading academic medical centers helping to deliver high quality care to its faculty and employees. She is currently helping IBM Watson Health bring cognitive computing and machine learning to advance the idea of Value-Based Care and help solve the pressing problems that physicians, employers and payers are facing.
Read More »